BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15613462)

  • 1. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome.
    Eisenhofer G; Huynh TT; Pacak K; Brouwers FM; Walther MM; Linehan WM; Munson PJ; Mannelli M; Goldstein DS; Elkahloun AG
    Endocr Relat Cancer; 2004 Dec; 11(4):897-911. PubMed ID: 15613462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas.
    Vogel TW; Brouwers FM; Lubensky IA; Vortmeyer AO; Weil RJ; Walther MM; Oldfield EH; Linehan WM; Pacak K; Zhuang Z
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3747-51. PubMed ID: 15769989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
    Huynh TT; Pacak K; Wong DL; Linehan WM; Goldstein DS; Elkahloun AG; Munson PJ; Eisenhofer G
    Ann N Y Acad Sci; 2006 Aug; 1073():241-52. PubMed ID: 17102092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas.
    Tömböl Z; Eder K; Kovács A; Szabó PM; Kulka J; Likó I; Zalatnai A; Rácz G; Tóth M; Patócs A; Falus A; Rácz K; Igaz P
    Mod Pathol; 2010 Dec; 23(12):1583-95. PubMed ID: 20818339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas.
    Bender BU; Gutsche M; Gläsker S; Müller B; Kirste G; Eng C; Neumann HP
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4568-74. PubMed ID: 11134110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma.
    Walther MM; Reiter R; Keiser HR; Choyke PL; Venzon D; Hurley K; Gnarra JR; Reynolds JC; Glenn GM; Zbar B; Linehan WM
    J Urol; 1999 Sep; 162(3 Pt 1):659-64. PubMed ID: 10458336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease.
    Neumann HP; Berger DP; Sigmund G; Blum U; Schmidt D; Parmer RJ; Volk B; Kirste G
    N Engl J Med; 1993 Nov; 329(21):1531-8. PubMed ID: 8105382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2.
    Koch CA; Mauro D; Walther MM; Linehan WM; Vortmeyer AO; Jaffe R; Pacak K; Chrousos GP; Zhuang Z; Lubensky IA
    Endocr Pathol; 2002; 13(1):17-27. PubMed ID: 12114747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes.
    Eisenhofer G; Walther MM; Huynh TT; Li ST; Bornstein SR; Vortmeyer A; Mannelli M; Goldstein DS; Linehan WM; Lenders JW; Pacak K
    J Clin Endocrinol Metab; 2001 May; 86(5):1999-2008. PubMed ID: 11344198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas.
    López-Jiménez E; Gómez-López G; Leandro-García LJ; Muñoz I; Schiavi F; Montero-Conde C; de Cubas AA; Ramires R; Landa I; Leskelä S; Maliszewska A; Inglada-Pérez L; de la Vega L; Rodríguez-Antona C; Letón R; Bernal C; de Campos JM; Diez-Tascón C; Fraga MF; Boullosa C; Pisano DG; Opocher G; Robledo M; Cascón A
    Mol Endocrinol; 2010 Dec; 24(12):2382-91. PubMed ID: 20980436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromogranin a expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
    Cleary S; Phillips JK; Huynh TT; Pacak K; Fliedner S; Elkahloun AG; Munson P; Worrell RA; Eisenhofer G
    Horm Metab Res; 2007 Dec; 39(12):876-83. PubMed ID: 18046660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma.
    Zeiger MA; Zbar B; Keiser H; Linehan WM; Gnarra JR
    Genes Chromosomes Cancer; 1995 Jul; 13(3):151-6. PubMed ID: 7669733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How many pathways to pheochromocytoma?
    Neumann HP; Hoegerle S; Manz T; Brenner K; Iliopoulos O
    Semin Nephrol; 2002 Mar; 22(2):89-99. PubMed ID: 11891502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.
    Eisenhofer G; Lenders JW; Linehan WM; Walther MM; Goldstein DS; Keiser HR
    N Engl J Med; 1999 Jun; 340(24):1872-9. PubMed ID: 10369850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas.
    Dannenberg H; De Krijger RR; van der Harst E; Abbou M; IJzendoorn Y; Komminoth P; Dinjens WN
    Int J Cancer; 2003 Jun; 105(2):190-5. PubMed ID: 12673678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
    Huynh TT; Pacak K; Brouwers FM; Abu-Asab MS; Worrell RA; Walther MM; Elkahloun AG; Goldstein DS; Cleary S; Eisenhofer G
    Eur J Endocrinol; 2005 Oct; 153(4):551-63. PubMed ID: 16189177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
    Jensen RL; Gillespie D; House P; Layfield L; Shelton C
    J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas.
    Gergics P; Patocs A; Toth M; Igaz P; Szucs N; Liko I; Fazakas F; Szabo I; Kovacs B; Glaz E; Racz K
    Eur J Endocrinol; 2009 Sep; 161(3):495-502. PubMed ID: 19574279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.